ATH-1105 – A next-generation, novel, orally administered, small molecule drug candidate in development for the potential treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative ...
A fundraiser has been launched for Will Vess, a 57-year-old retired United States Air Force veteran who was recently ...
6h
Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline ...
Ten years after her sexual assault, she discovered that the evidence in her rape kit hadn’t been tested — and neither had ...
The event was initially reported as motor neuropathy, which was later defined as amyotrophic lateral sclerosis (ALS), a ...
Our pipeline includes programs for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and ...
The event was initially reported as motor neuropathy, which was later defined as amyotrophic lateral sclerosis (ALS), a ...
Galantamine slowed decline in cognitive function, functional ability, and behavior at 6 months in people with Alzheimer's ...
The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...
The event, originally described as motor neuropathy, was later reclassified as amyotrophic lateral sclerosis. The FDA requested additional information, which Novavax provided, confirming that the ...
Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback